Utilizing devTOXqP in a Combined Testing Approach for Identifying Developmental Toxicity Liability of Chemicals [Webinar Slides]
Aug 16, 2017Why develop devTOX? Reduce prevalence of birth defects and decrease animal testing. Our approach represents a unique opportunity to screen compound safety using a human endpoint. devTOX quickPredict is a predictive, targeted biomarker assay. (devTOX Discovery, on the other hand, is a predictive, untargeted metabolomics assay.) Jessica Palmer presented this webinar in October 2016. If
Presentation slides: Stemina participates in platform session at Teratology Society Annual Meeting
Jun 26, 2017Presented at the Teratology Society’s 57th Annual Meeting in Denver, Colorado in June 2017 by Stemina’s Associate Director of Toxicology, Jessica Palmer. Previous approaches for evaluating the accuracy of alternative test methods have been based on the classification of a chemical as either a positive or negative, with no other distinction. This method does not
Stemina’s Jessica Palmer to Present at Teratology Society Annual Meeting
Jun 14, 2017Jessica Palmer, Stemina’s Associate Director of Toxicology, will present at the Teratology Society’s 57th Annual Meeting, held June 24-28, 2017 in Denver. Anyone interested in developmental toxicity assays is encouraged to attend. Prediction of Developmental Toxicity Potential by In Vivo Exposures with a Biomarker-Based Human Pluripotent Stem Cell Assay This presentation is part of Platform
Stemina to Present Sponsored Session, Poster at SOT’s Annual Meeting & ToxExpo 2017
Feb 20, 2017Stemina Biomarker Discovery will be well represented at the Society of Toxicology’s 56th Annual Meeting and ToxExpo. In addition to participating in SOT as an exhibitor (booth 2506), Stemina’s Jessica Palmer, Associate Director of Toxicology, will present new research in two sessions: Poster session: Monday, March 13th | 9:30 AM – 12:45 PM | P331
Stemina Hosts Webinar: Exposure-Based Developmental Toxicity Prediction with the devTOX quickPredict Assay
Jan 18, 2017The required in vivo preclinical models for developmental toxicity testing have varying degrees of concordance with human effects, having approximately 70% concordance to known human developmental toxins. Development and validation of alternative methods for assessing developmental toxicity potential, such as the devTOX quickPredict assay (devTOXqP) would decrease the time, expense, and use of vertebrate animals.
Stemina Hosts Session at SOT 2016
Apr 11, 2016Follow the link to view the presentation from Stemina’s session at SOT: Practical Application of a Human Stem Cell Assay for Developmental Toxicity Testing
Laura Egnash Speaks at ASMS Agilent Users Meeting
Jun 8, 2013Laura Egnash was invited to speak at the Agilent Users’ Meeting in Minneapolis on June 8, 2013 at the American Society of Mass Spectrometry annual conference. Follow the link at right to view her full presentation, “Applying Metabolomics for Novel Biomarker Discovery and Commercial Assay Development.”
Stemina Hosts Session at SOT 2013
May 29, 2013Stemina’s CEO, Beth Donley, presented Stemina’s new in vitro assay for prediction of developmental toxicity: devTOX quickPredict.
Dr. Paul West Speaks at ASMS Agilent Users Meeting
May 22, 2010Paul West was invited to speak at the Agilent Users Meeting in Salt Lake City on May 22, 2010 at the American Society of Mass Spectrometry annual meeting. Follow the link at right to view his full presentation, “Discovering Biomarkers of Human Disease and Development Using Stem Cells and Metabolomics.”
Dr. Paul West Presents Webinar
Sep 23, 2009Paul West was invited to present at a Genetic Engineering News & Biotechnology Webinar, “Advances in Compound Identification Using Metabolomics”. The primary focus of Dr. West’s presentation entitled “De Novo Metabolite Chemical Structure Determination” is metabolite chemical structure determination using LC-MS, accurate mass and MS-MS. The Webinar was presented on September 23, 2009.